ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development

References

• Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93(21),11349–353 (1996).
   Google Scholar
• Taylor J, Tartaglia J, Riviere M et al. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev. Biol. Stand. 82,131–135 (1994).
   Google Scholar
• Carroll MW Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8(5), 573–577 (1997).
   Google Scholar
• Mackett M, Smith GL, Moss B.General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Vim!. 49(3), 857–864 (1984).
   Google Scholar
• Davison AJ, Moss B. Structure of vaccinia virus early promoters. J. Mal Biol. 210(4), 749–769 (1989).
   PubMed Web of Science ®Google Scholar
• Davison AJ, Moss B.Structure of vaccinia virus late promoters. J. Mal Biol. 210(4), 771–784 (1989).
   Google Scholar
• Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of canarypox virus. Viral 78(1), 353–366 (2004).
   PubMed Web of Science ®Google Scholar
• Gubser C, Hue S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J. Gen. Viral 85\(Pt 1), 105–117 (2004).
   Google Scholar
• de Bruyn G, Rossini AJ, Chiu Y1 et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22(5–6), 705–714 (2004).
   Google Scholar
• •Comprehensive review of the safety data of many ALVAC-HIV studies.
   Google Scholar
• Gilbert PB, Chiu YL, Allen M et al, NIAID. HIV Vaccine Trials Network.Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21(21–22), 2933–2947 (2003).
   Google Scholar
• Clements-Mann ML, Weinhold K, Matthews TJ et al. Immune responses to human immunodeficiency virus (H1V) Type 1 induced by canarypox expressing HIV-1MN gp120, HIV-15F2 recombinant gp120, or both vaccines in seronegative adults. MAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177(5), 1230–1246 (1998).
   Google Scholar
• Belshe RB, Gorse GJ, Mulligan MJ et al MAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS12(18), 2407–2415 (1998).
   Google Scholar
• Salmon-Ceron D, Excler JL, Finkielsztejn L et al. Safety and immunogenicity of a live recombinant canarypox virus expressing tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L Agence Res. Hum. Retroviruses 15 (7), 633–645 (1999).
   Google Scholar
• Evans TG, Keefer MC, Weinhold KJ et al A canarypox vaccine expressing multiple human immunodeficiency virus Type 1 genes given alone or with rgp120 elicits broad and durable CD8* cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180(2), 290–298 (1999).
   Google Scholar
• Belshe RB, Stevens C, Gorse GJ et al, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a Phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183(9), 1343–1352 (2001).
   Google Scholar
• Gupta K, Hudgens M, Corey L et al, AIDS Vaccine Evaluation Group.Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. Acquir Immune Defic Synth: 29(3), 254–261 (2002).
   Google Scholar
• Cao H, Kaleebu P, Hom D et at, HIV Network for Prevention Trials. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187(6), 887–895 (2003).
   Google Scholar
• Mulligan MJ, Weber J. Human trials of HIV-1 vaccines. AIDS 13(Suppl. A) S105—S112 (1999).
   Google Scholar
• •Outstanding review on milestones with HIV vaccines with a large amount of information on the ALVAC experience.
   Google Scholar
• Spearman P HIV Vaccine Development: Lessons from the past and promise for the future. Current HIV Res.1,101–120 (2003).
   Google Scholar
• Graham BS. Clinical trials of HIV vaccines. Ann. Rev Merl 53,207–221 (2002).
   PubMedGoogle Scholar
• Graham BS, McElrath MJ, Connor RI et al. Analysis of intercurrent human immunodeficiency virus Type 1 infections in Phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group and the Correlates of HIV Immune Protection Group. J. Infect. Dis. 177(2), 310–319 (1998).
   Google Scholar
• Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Merl 2(4), 405–411 (1996).
   Google Scholar
• McNeil AJ, Yap PL, Gore SM et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM89(3), 177–185 (1996).
   Google Scholar
• Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, Schachter F, Zagury D, Rappaport J, Winkler C, Nelson GW, Zagury JF. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol 162(11), 6942–6946 (1999).
   PubMed Web of Science ®Google Scholar
• Costello C, Tang J, Rivers C et al HLA- B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS13 (14), 1990-1991 (1999).
   Google Scholar
• •Confirmation that African HLA B5703, closely related to Causcasian HLA B5701, similarly confers protection.
   Google Scholar
• Migueles SA, Sabbaghian MS, Shupert WL et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected longterm nonprogressors. Proc. Natl Acad. Sci USA 97(6), 2709–2714 (2000).
   Google Scholar
• Gao X, Nelson GW, Karacki P et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Eng J Merl 344(22),1668–1675 (2001).
   Google Scholar
• Mary Carrington, Stephen J. O'Brien The influence of HLA genotypes on AIDS. Ann. Rev Merl 54,535–551 (2003).
   Google Scholar
• Kaslow RA, Rivers C, Tang J et al, NIAID AIDS vaccine evaluation group. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) Type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Viral 75(18), 8681–8689 (2001).
   Google Scholar
• ••Landmark study that reports theassociation with vaccine response in HLA carriers with favorable HIV infection prognosis.
   Google Scholar
• Marovich M, Mascola J, Eller M et al. 'Preparation of Clinical Grade ALVAC-HIV vaccine loaded human dendritic cells'. J. Infect. Dis.186,1242–1252 (2002).
   Google Scholar
• Marovich M, Mascola M, Eller M et al ALVAC-HIV (vCP205) Loaded Autologous DC as an HIV Vaccine Strategy' Proc. XIIIth Cent. Carries Symp. 127–132 (2003).
   Google Scholar
• Musey L, Ding Y, Elizaga M, Ha R, Celum C, McElrath MJ. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. Immune]. 171(2), 1094–1101 (2003).
   Google Scholar
• •Study shows HIV specific mucosal immunity after sytemic administration of vaccine.
   Google Scholar
• Wright PF, Mestecky J, McElrath MJ et al, National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 'Comparison of systemic and mucasal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein'.j infect. Dis: 189(7), 1221–1231 (2004).
   Google Scholar
• Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection. Vaccine 17(4), 308–318 (1998).
   Google Scholar
• Chen HD, Fraire AE, Joris I, Brehm MA,Welsh RM, Selin LK. Memory CD8 T cells in heterologous antiviral immunity and immunopathology in the lung. Nature Immune]. 2,1067-1076 (2001).
   Google Scholar
• •Excellent study reviewing heterologous immunity.
   Google Scholar
• Ferrari G, Humphrey W McElrath MJ et al Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Nail Acad. Li. USA 94(4), 1396–1401 (1997).
   Google Scholar
• ••Study shows cross-clade reactivity inALVAC vaccinees.
   Google Scholar